Related Experiment Videos
Antifungal prophylaxis in hematopoietic stem cell transplant recipients
1Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109, USA. kmarr@fhcrc.org
Abstract:
Infections remain a major complication of hematopoietic stem cell transplantation, with recent trends indicating that fungal pathogens have become one of the most common causes of death. Attention has turned to the use of prophylactic antifungal medications to prevent infection with both Candida and Aspergillus species. Recent studies, which are reviewed within, indicate success in preventing infections caused by azole-susceptible Candida species, accompanied by improved transplant-related mortality rates in high-risk patients. Further studies are necessary to develop strategies to prevent infection with Aspergillus species.
Insights
Prophylactic antifungal medications show success in preventing Candida infections after hematopoietic stem cell transplantation, improving survival rates. Further research is needed to combat Aspergillus infections in these high-risk patients.
Area of Science:
- Hematology
- Infectious Diseases
- Transplantation Medicine
Background:
- Infections are a significant risk following hematopoietic stem cell transplantation (HSCT).
- Fungal infections, particularly from Candida and Aspergillus species, are increasingly recognized as a leading cause of mortality in HSCT recipients.
- Prophylactic antifungal strategies are being explored to mitigate these risks.
Purpose of the Study:
- To review recent studies on the efficacy of prophylactic antifungal medications in HSCT patients.
- To assess the impact of these strategies on preventing infections caused by Candida and Aspergillus species.
- To identify areas for future research in antifungal prophylaxis for HSCT.
Main Methods:
- Review of recent clinical studies and literature on antifungal prophylaxis in HSCT.
- Analysis of data regarding the prevention of Candida and Aspergillus infections.
- Evaluation of transplant-related mortality rates in patients receiving antifungal prophylaxis.
Main Results:
- Prophylactic antifungal medications have demonstrated success in preventing infections caused by azole-susceptible Candida species.
- Improved transplant-related mortality rates were observed in high-risk patients treated with these prophylactic agents.
- Current strategies require further development to effectively prevent Aspergillus species infections.
Conclusions:
- Antifungal prophylaxis is a valuable strategy for reducing Candida infections and improving outcomes in HSCT.
- Effective prevention of Aspergillus infections remains a challenge and requires further investigation.
- Optimizing antifungal prophylaxis is crucial for enhancing patient survival after HSCT.